Background: Metastatic breast cancer, particularly that which expresses the HER2 receptor, poses a significant therapeutic challenge in oncology, often associated with an unfavorable prognosis.

The DESTINY-Breast11 trial (ClinicalTrials.gov Identifier: NCT05113251) evaluated the efficacy and safety of trastuzumab deruxtecan as a neoadjuvant therapy in 927 participants aged 18 years and ...

Key Takeaways Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% ...

Send comments and news tips to [email protected]. Cite this: Edited by Katie Lennon. Trastuzumab Duocarmazine Ups PFS, Ocular Toxicity in Advanced HER2+ Breast Cancer - Medscape - October 31, 2024.

Patients with early breast cancer when trastuzumab was given as neoadjuvant therapy (RR, 1.30; 95% CI, 0.47-3.59; with consistency across studies, I2 = 0%; P =.57).

Accord BioPharma announced that the FDA has approved Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor receptor 2 ...

Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

Trastuzumab is a HER2/neu receptor antagonist marketed as Herceptin ® by Roche and its Genentech subsidiary. The open-label, multi-center, dose escalation and dose optimization trial has an ...

Hurvitz explains that at the time, oncologists had never seen such impressive results with any therapy for HER2-positive breast cancer. These data led to the accelerate approval of T-DXd. Then, in the ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for [vic-]trastuzumab duocarmazine (SYD985) for the treatment of patients with HER2-positive ...

Trastuzumab deruxtecan (5.4 mg/kg) is approved in Canada, Israel and the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a ...